Josh Eckman


Since founding Wasatch in 2005, Mr. Eckman has been instrumental in securing funding, attracting key employees and advisors, developing strategic partnerships, designing Wasatch’s proprietary flexible manufacturing process, securing international distributorships, and building out the sales channels for current products. Mr. Eckman previously worked with the Lassonde New Venture Development Center, moving university technologies into the marketplace. Mr. Eckman graduated summa cum laude in Business Administration and Asian Studies from the University of Utah. At graduation, he was awarded the Outstanding Scholar in Business Administration and the Honors Baccalaureate Award. Mr. Eckman also received a M.S. in Mechanical Engineering (microfluidics focus) from the University of Utah.

Bruce Gale, PhD


In addition to his position at Wasatch, Dr. Gale is an Associate Professor in Mechanical Engineering at the University of Utah, with concurrent appointments in Bioengineering, Material Science, Electrical and Computer Engineering. He has conducted research in microarray spotter manufacturing, microscale biomolecule sample preparation, microneedle fabrication, micropumps, bioMEMS, particle separations, optical waveguides, and DNA amplification. Dr. Gale has extensive experience with the management of research projects, and has served as the principal investigator on a number of state and federally funded projects. Dr. Gale graduated summa cum laude in Mechanical Engineering from Brigham Young University and received his Ph.D. in Bioengineering from the University of Utah.

Gary Sams, PhD


Dr. Gary Sams has worked as a Sales and Marketing executive for over 20 years in the life sciences research and drug discovery tools sectors. He has played pivotal roles at Promega, EG&G, Digene and Vysis (acquired by Abbott for $350MM in 2002). For the past five years Dr. Sams has worked as a Managing Partner of Beachhead Consulting Group. The Group’s clients include Applied Biosystems, Invitrogen, Perkin Elmer, and Caliper. Dr. Sams has also worked with many early-stage companies, including 454, Cytokinetics, Sequenom, and Nanogen. Prior to entering the commercial sector, Dr. Sams received his Ph.D. in Cell Biology from the University of Kansas and completed a post-doctoral fellowship in Cancer Molecular Biology at the University of Wisconsin.

Joseph D. Keegan, PhD


Dr. Keegan has more than 30 years of experience in life science businesses. Most recently as CEO at ForteBio, Inc. he led the Series C financing which raised $25M, established product development and sales strategies that resulted in 2007-11 compounded annual revenue growth of 45% to $27M. During his 9 year tenure as CEO at Molecular Devices Corporation, he grew the company’s revenues from $30M to $185M through internal growth and acquisitions. In early 2007, he oversaw its acquisition by MDS Corporation for $615M.  He currently serves on the Board of Directors of ALDA as Immediate Past Chairman, Advanced Cell Diagnostics, Labcyte Corporation as Chairman, Response Biomedical Corp (RBM:Toronto), Seahorse Bioscience Inc., Stereotaxis, Inc. (Nasdaq: STXS) and the San Francisco Opera. Dr. Keegan holds a B.A. in Chemistry from Boston University and a Ph.D. in Physical Chemistry from Stanford University.

[vc_widget_sidebar sidebar_id=”about-us-submenu”]